Tessa Marburger

Nuclear localization of leukotriene A4 hydrolase in type II alveolar epithelial cells in normal and fibrotic lung.

M. Peters-Golden, R. Paine, T. Brock, 2005, American journal of physiology. Lung cellular and molecular physiology.

Reply: 3,4-diaminopyridine in LEMS: Concerns regarding presentation of previous studies

D. Richman, A. Peltier, A. Smith, 2018 .

Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey

Sanjiv J. Shah, M. Emdin, N. Sarswat, 2021, JACC. CardioOncology.

Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update

M. Emdin, N. Sarswat, C. Rapezzi, 2022, Orphanet Journal of Rare Diseases.

Eculizumab improves fatigue in refractory generalized myasthenia gravis

K. Patra, P. van Damme, M. Benatar, 2019, Quality of Life Research.

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.

G. L. Masson, W. Löscher, P. Vermersch, 2017, The Lancet. Neurology.

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

P. van Damme, M. Benatar, F. Piehl, 2019, Journal of the Neurological Sciences.

‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

P. van Damme, M. Benatar, F. Piehl, 2020, Journal of Neurology.

3,4‐diaminopyridine base effectively treats the weakness of Lambert‐Eaton myasthenia

D. Richman, K. Aleš, A. Peltier, 2018, Muscle & nerve.

Reply

D. Richman, A. Peltier, A. Smith, 2018, Muscle and Nerve.